BELLUS Health’s portfolio focuses on novel therapeutics for conditions with high unmet medical need.

Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

BLU-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BELLUS Health announced on July 9, 2018 the initiation of healthy subjects dosing in a Phase 1 clinical study for BLU-5937 for the treatment of chronic cough. Results of the Phase 1 clinical study are expected in the fourth quarter of 2018. Preclinical studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception, with an excellent safety profile. BLU-5937 has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. A recent commercial assessment performed by Torreya Insights on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.

BELLUS Health also has economic interests in other partnered clinical-stage drug development programs, including KIACTA™ for sarcoidosis, AMO-01 for Phelan McDermid Syndrome and ALZ-801 for APOE4 homozygous Alzheimer’s disease.

 

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.